Literature DB >> 22665375

Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.

Maria Kostakioti1, Maria Hadjifrangiskou, Corinne K Cusumano, Thomas J Hannan, James W Janetka, Scott J Hultgren.   

Abstract

Urinary tract infections (UTI), primarily caused by uropathogenic Escherichia coli (UPEC), are one of the leading bacterial infections due to their high frequency and rate of recurrence. Both type 1 pilus adhesive organelles (fim) and the QseC sensor kinase have been implicated in UPEC virulence during UTI and have been individually reported to be promising drug targets. Deletion of qseC leads to pleiotropic effects due to unregulated activation of the cognate response regulator QseB, influencing conserved metabolic processes and diminishing expression of virulence genes, including type 1 pili. Here, we discern the type 1 pilus-dependent and -independent effects that contribute to the virulence attenuation of a UPEC qseC deletion mutant in a murine model of experimental UTI. We show that although a ΔqseC mutant restored for type 1 pilus expression regains the ability to colonize the host and initiate acute infection up to 16 h postinfection, it is rapidly outcompeted during acute infection when coinoculated with a wild-type strain. As a result, this strain has a diminished capacity to establish chronic infection. A prophylactic oral dose of a FimH small-molecular-weight antagonist (ZFH-02056) further reduced the ability of the qseC mutant to establish chronic infection. Thus, loss of QseC significantly enhances the efficacy of ZFH-02056. Collectively, our work indicates that type 1 pili and QseC become critical in different infection stages, and that dual targeting of these factors has an additive effect on ablating UPEC virulence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665375      PMCID: PMC3434567          DOI: 10.1128/IAI.00283-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection.

Authors:  K Thankavel; B Madison; T Ikeda; R Malaviya; A H Shah; P M Arumugam; S N Abraham
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization.

Authors:  Kelly J Wright; Patrick C Seed; Scott J Hultgren
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.

Authors:  M A Mulvey; Y S Lopez-Boado; C L Wilson; R Roth; W C Parks; J Heuser; S J Hultgren
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

4.  Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.

Authors:  Julie Bouckaert; Jenny Berglund; Mark Schembri; Erwin De Genst; Lieve Cools; Manfred Wuhrer; Chia-Suei Hung; Jerome Pinkner; Rikard Slättegård; Anton Zavialov; Devapriya Choudhury; Solomon Langermann; Scott J Hultgren; Lode Wyns; Per Klemm; Stefan Oscarson; Stefan D Knight; Henri De Greve
Journal:  Mol Microbiol       Date:  2005-01       Impact factor: 3.501

5.  Distinct glycan structures of uroplakins Ia and Ib: structural basis for the selective binding of FimH adhesin to uroplakin Ia.

Authors:  Bo Xie; Ge Zhou; Shiu-Yung Chan; Ellen Shapiro; Xiang-Peng Kong; Xue-Ru Wu; Tung-Tien Sun; Catherine E Costello
Journal:  J Biol Chem       Date:  2006-03-27       Impact factor: 5.157

6.  Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection.

Authors:  Jennifer A Snyder; Amanda L Lloyd; C Virginia Lockatell; David E Johnson; Harry L T Mobley
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

7.  Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach.

Authors:  Swaine L Chen; Chia-Seui Hung; Jian Xu; Christopher S Reigstad; Vincent Magrini; Aniko Sabo; Darin Blasiar; Tamberlyn Bieri; Rekha R Meyer; Philip Ozersky; Jon R Armstrong; Robert S Fulton; J Phillip Latreille; John Spieth; Thomas M Hooton; Elaine R Mardis; Scott J Hultgren; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

8.  Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women.

Authors:  R Ikäheimo; A Siitonen; T Heiskanen; U Kärkkäinen; P Kuosmanen; P Lipponen; P H Mäkelä
Journal:  Clin Infect Dis       Date:  1996-01       Impact factor: 9.079

9.  Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.

Authors:  I Connell; W Agace; P Klemm; M Schembri; S Mărild; C Svanborg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  In vivo phase variation of Escherichia coli type 1 fimbrial genes in women with urinary tract infection.

Authors:  J K Lim; N W Gunther; H Zhao; D E Johnson; S K Keay; H L Mobley
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more
  23 in total

1.  Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection.

Authors:  Swaine L Chen; Meng Wu; Jeffrey P Henderson; Thomas M Hooton; Michael E Hibbing; Scott J Hultgren; Jeffrey I Gordon
Journal:  Sci Transl Med       Date:  2013-05-08       Impact factor: 17.956

2.  Purine Biosynthesis Metabolically Constrains Intracellular Survival of Uropathogenic Escherichia coli.

Authors:  Carrie L Shaffer; Ellisa W Zhang; Anne G Dudley; Beverly R E A Dixon; Kirsten R Guckes; Erin J Breland; Kyle A Floyd; Daniel P Casella; Holly M Scott Algood; Douglass B Clayton; Maria Hadjifrangiskou
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

Review 3.  From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections.

Authors:  Jennifer A Silverman; Henry L Schreiber; Thomas M Hooton; Scott J Hultgren
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

4.  The Histidine Residue of QseC Is Required for Canonical Signaling between QseB and PmrB in Uropathogenic Escherichia coli.

Authors:  Erin J Breland; Ellisa W Zhang; Tomas Bermudez; Charles R Martinez; Maria Hadjifrangiskou
Journal:  J Bacteriol       Date:  2017-08-22       Impact factor: 3.490

Review 5.  Small Molecules That Sabotage Bacterial Virulence.

Authors:  Benjamin K Johnson; Robert B Abramovitch
Journal:  Trends Pharmacol Sci       Date:  2017-02-14       Impact factor: 14.819

Review 6.  Bacterial signaling as an antimicrobial target.

Authors:  Melissa Ellermann; Vanessa Sperandio
Journal:  Curr Opin Microbiol       Date:  2020-09-08       Impact factor: 7.934

Review 7.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

8.  Strong cross-system interactions drive the activation of the QseB response regulator in the absence of its cognate sensor.

Authors:  Kirsten R Guckes; Maria Kostakioti; Erin J Breland; Alice P Gu; Carrie L Shaffer; Charles R Martinez; Scott J Hultgren; Maria Hadjifrangiskou
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-23       Impact factor: 11.205

9.  Adenylate cyclase and the cyclic AMP receptor protein modulate stress resistance and virulence capacity of uropathogenic Escherichia coli.

Authors:  Grant T Donovan; J Paul Norton; Jean M Bower; Matthew A Mulvey
Journal:  Infect Immun       Date:  2012-10-31       Impact factor: 3.441

10.  Defining a Molecular Signature for Uropathogenic versus Urocolonizing Escherichia coli: The Status of the Field and New Clinical Opportunities.

Authors:  Allison R Eberly; Connor J Beebout; Ching Man Carmen Tong; Gerald T Van Horn; Hamilton D Green; Madison J Fitzgerald; Shuvro De; Emily K Apple; Alexandra C Schrimpe-Rutledge; Simona G Codreanu; Stacy D Sherrod; John A McLean; Douglass B Clayton; Charles W Stratton; Jonathan E Schmitz; Maria Hadjifrangiskou
Journal:  J Mol Biol       Date:  2019-11-30       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.